ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

Study Identifier:
COAV101B1US01
ClinicalTrials.gov Identifier:
NCT07448610
EudraCT Identifier:
N/A
EU CT Number:
N/A
Sponsor:
Novartis Pharmaceuticals
Recruiting

Study Details

Medical Condition
  • All Spinal Muscular Atrophies
Study Drug
  • Drug: Onasemnogene Abeparvovec-brve
Date
Aug 2026 - May 2032
Phase 1
Phase 2
Phase 3
Phase 4
Patient Requirements
Sex: Female & Male
Age: 2 - 100 Years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • A participant will be enrolled in STREAM only if all the following conditions are met:
  • The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).
  • He or she is ≥ 2 years of age on the day of the intrathecal injection.
  • The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.
  • One of the following functional categories applies at screening:
  • independently ambulatory child/adolescent 2 - \<18 years; or
  • independently ambulatory adult (≥ 18 years).
  • non-ambulatory (includes walkers with assistance) adult \> 18 years with entry level RULM at baseline
  • At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.
Exclusion Criteria
  • A participant will be excluded if any of the following conditions apply:
  • Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
  • An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
  • Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
  • Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
  • Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.
  • Other protocol inclusion, exclusion criteria may apply.

Protocol Summary

The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).

Trial Locations

Location
Status
Location
Columbia University Medical Center
New York, New York, United States, 10032
Status
Recruiting

Contact Cure SMA

User Information

If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.

  • Disability Advocate who does not have SMA
  • I am a healthcare provider
  • I am a researcher
  • I have no direct connection to SMA
  • I have SMA
  • I lost a child to SMA
  • My child has SMA
  • Someone close to me has/had SMA
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • India
  • Ireland
  • Israel
  • Italy
  • Japan
  • Lebanon
  • Malaysia
  • Mexico
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Republic of Korea
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.